C-Medical Sverige AB Revenue and Competitors
Estimated Revenue & Valuation
- C-Medical Sverige AB's estimated annual revenue is currently $2.4M per year.
- C-Medical Sverige AB's estimated revenue per employee is $162,000
Employee Data
- C-Medical Sverige AB has 15 Employees.
- C-Medical Sverige AB grew their employee count by 0% last year.
C-Medical Sverige AB's People
| Name | Title | Email/Phone |
|---|
C-Medical Sverige AB Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $15.5M | 66 | -31% | $43M | N/A |
#2 | $143.1M | 424 | -7% | N/A | N/A |
#3 | $26.7M | 99 | 6% | N/A | N/A |
#4 | $22.7M | 84 | 0% | N/A | N/A |
#5 | $29.7M | 110 | 22% | N/A | N/A |
#6 | $27M | 100 | 12% | $28.2M | N/A |
#7 | $4.9M | 26 | 4% | N/A | N/A |
#8 | $6.5M | 30 | -6% | N/A | N/A |
#9 | $1194.9M | 3161 | 7% | N/A | N/A |
#10 | $1074.7M | 2843 | 10% | N/A | N/A |
What Is C-Medical Sverige AB?
C-Medical är Skandinaviens ledande vårdgivare inom urologi med speciellt fokus på diagnostik och kirurgi vid prostatacancer. Vi har tio kliniker runt om i landet och avancerad robotkirurgi på Sophiahemmet och Löwenströmska Sjukhuset i Stockholm samt Carlanderska Sjukhuset i Göteborg.
keywords:N/A
N/A
Total Funding
15
Number of Employees
$2.4M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
C-Medical Sverige AB News
Diamyd Medical's B-share is traded on Nasdaq First North Growth Market under the ticker DMYD B. FNCA Sweden AB is the Company's Certified...
Sambandet ger också ytterligare stöd till betydelsen av C-peptid som ett meningsfullt så kallat surrogatmått ... Diamyd Medical AB (publ)
Address: AAK AB, c/o Euroclear Sweden AB, Box 191, ... Other benefits may include, for example, life insurance, medical insurance (Sw:...
Other Companies in Stockholm
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $1.7M | 15 | -50% | N/A |
#2 | $1.3M | 15 | 7% | N/A |
#3 | $1.3M | 15 | -35% | N/A |
#4 | $2.2M | 15 | 25% | N/A |
#5 | $1.3M | 15 | -32% | N/A |